ONC201新薬の考察と市場予測 - 2032年

当レポートでは、主要7市場（米国、ドイツ、フランス、イタリア、スペイン、英国、日本）におけるONC201について調査分析し、作用機序、用法と用量、研究開発活動に関する考察や、市場予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 多形性膠芽腫（GBM）におけるONC201の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品のプロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新治療法）

第5章 ONC201市場の評価

• 多形性膠芽腫（GBM）におけるONC201の市場見通し
• 主要7市場の分析
  • 主要7市場の多形性膠芽腫（GBM）向けONC201の市場規模
• 市場の分析：国別
  • 米国の多形性膠芽腫（GBM）向けONC201の市場規模
  • ドイツの多形性膠芽腫（GBM）向けONC201の市場規模
  • 英国の多形性膠芽腫（GBM）向けONC201の市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: ONC201, Clinical Trial Description, 2023
• Table 2: ONC201, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: ONC201 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: ONC201 Market Size in the US, in USD million (2019-2032)
• Table 7: ONC201 Market Size in Germany, in USD million (2019-2032)
• Table 8: ONC201 Market Size in France, in USD million (2019-2032)
• Table 9: ONC201 Market Size in Italy, in USD million (2019-2032)
• Table 10: ONC201 Market Size in Spain, in USD million (2019-2032)
• Table 11: ONC201 Market Size in the UK, in USD million (2019-2032)
• Table 12: ONC201 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: ONC201 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: ONC201 Market Size in the United States, USD million (2019-2032)
• Figure 3: ONC201 Market Size in Germany, USD million (2019-2032)
• Figure 4: ONC201 Market Size in France, USD million (2019-2032)
• Figure 5: ONC201 Market Size in Italy, USD million (2019-2032)
• Figure 6: ONC201 Market Size in Spain, USD million (2019-2032)
• Figure 7: ONC201 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: ONC201 Market Size in Japan, USD million (2019-2032)

“"ONC201 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about ONC201 for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the ONC201 for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ONC201 for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ONC201 market forecast analysis for GBM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary:

A novel therapeutic intervention of imipridone class is in development by Oncoceutics (acquired by Chimerix), i.e., ONC201, a highly selective antagonist of dopamine receptor D2 (DRD2) and ClpP agonist that can penetrate the blood-brain barrier effectively. ONC201 engages proven anticancer pathways that lead to apoptosis in cancer cells. It is a small molecule originally identified as a TNF-related apoptosis-inducing ligand (TRAIL)-inducing compound. It has a unique ability to induce the expression of both pro-death ligand TRAIL and its receptor DR5 through the engagement of the cellular integrated stress response (ISR) pathway. ONC201 has demonstrated single-agent efficacy in eliminating cancer stem cells CSCs in glioblastoma multiforme (GBM), colorectal, and prostate cancer models.

The drug targets multiple brain cancer indications, such as GBM and diffuse intrinsic pontine gliomas or diffuse midline glioma altogether. It has been found in early results that this drug can kill cancer cells but not normal cells and may be effective in patients with a specific genetic mutation in their tumor: the H3 K27M mutation. Primarily, this mutation occurs in tumors that occur in the midline region of the brain (thalamus, pons, spinal cord).

Chimerix planned to meet with the FDA in the first half of 2022 to review the design for the ONC201 first-line randomized placebo-controlled, Phase III trial in combination with radiation therapy that is planned to initiate in the second half of 2022 in patients who harbor the H3 K27M mutation.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ONC201 description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).
• Elaborated details on ONC201 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ONC201 research and development activities in GBM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ONC201.
• The report contains forecasted sales of ONC201 for GBM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for GBM.
• The report also features the SWOT analysis with analyst views for ONC201 in GBM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ONC201 Analytical Perspective by DelveInsight

In-depth ONC201 Market Assessment

This report provides a detailed market assessment of ONC201 for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

ONC201 Clinical Assessment

The report provides the clinical trials information of ONC201 for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ONC201 dominance.
• Other emerging products for GBM are expected to give tough market competition to ONC201 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ONC201 in GBM.
• Our in-depth analysis of the forecasted sales data of ONC201 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ONC201 in GBM.

Key Questions:

• What is the product type, route of administration and mechanism of action of ONC201?
• What is the clinical trial status of the study related to ONC201 in glioblastoma multiforme (GBM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ONC201 development?
• What are the key designations that have been granted to ONC201 for GBM?
• What is the forecasted market scenario of ONC201 for GBM?
• What are the forecasted sales of ONC201 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ONC201 for GBM?
• Which are the late-stage emerging therapies under development for the treatment of GBM?

Table of Contents

1. Report Introduction

2. ONC201 Overview in GBM

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. ONC201 Market Assessment

• 5.1. Market Outlook of ONC201 in GBM
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of ONC201 in the 7MM for GBM
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of ONC201 in the United States for GBM
  • 5.3.2. Market Size of ONC201 in Germany for GBM
  • 5.3.3. Market Size of ONC201 in France for GBM
  • 5.3.4. Market Size of ONC201 in Italy for GBM
  • 5.3.5. Market Size of ONC201 in Spain for GBM
  • 5.3.6. Market Size of ONC201 in the United Kingdom for GBM
  • 5.3.7. Market Size of ONC201 in Japan for GBM

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options